Prognostic factors in giant cell arteritis associated aortitis with PET/CT and CT angiography at diagnosis.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
04 2023
Historique:
received: 12 12 2022
revised: 26 01 2023
accepted: 06 02 2023
pubmed: 22 2 2023
medline: 4 3 2023
entrez: 21 2 2023
Statut: ppublish

Résumé

Prognosis data on giant-cell arteritis (GCA)-associated aortitis are scarce and heterogeneous. The aim of this study was to compare the relapses of patients with GCA-associated aortitis according to the presence of aortitis on CT-angiography (CTA) and/or on FDG-PET/CT. This multicenter study included GCA patients with aortitis at diagnosis; each case underwent both CTA and FDG-PET/CT at diagnosis. A centralized review of image was performed and identified patients with both CTA and FDG-PET/CT positive for aortitis (Ao-CTA+/PET+); patients with positive FDG-PET/CT but negative CTA for aortitis (Ao-CTA-/PET+), and patients solely positive on CTA. Eighty-two patients were included with 62 (77%) of female sex. Mean age was 67±8 years; 64 patients (78%) were in the Ao-CTA+/PET+ group; 17 (22%) in the Ao-CTA-/PET+ group and 1 had aortitis only on CTA. Overall, 51 (62%) patients had at least one relapse during follow-up: 45/64 (70%) in the Ao-CTA+/PET+ group and 5/17 (29%) in the Ao-CTA-/PET+ group (log rank, p = 0.019). In multivariate analysis, aortitis on CTA (Hazard Ratio 2.90, p = 0.03) was associated with an increased risk of relapse. Positivity of both CTA and FDG-PET/CT for GCA-related aortitis was associated with an increased risk of relapse. Aortic wall thickening on CTA was a risk factor of relapse compared with isolated aortic wall FDG uptake.

Sections du résumé

BACKGROUND
Prognosis data on giant-cell arteritis (GCA)-associated aortitis are scarce and heterogeneous. The aim of this study was to compare the relapses of patients with GCA-associated aortitis according to the presence of aortitis on CT-angiography (CTA) and/or on FDG-PET/CT.
METHODS
This multicenter study included GCA patients with aortitis at diagnosis; each case underwent both CTA and FDG-PET/CT at diagnosis. A centralized review of image was performed and identified patients with both CTA and FDG-PET/CT positive for aortitis (Ao-CTA+/PET+); patients with positive FDG-PET/CT but negative CTA for aortitis (Ao-CTA-/PET+), and patients solely positive on CTA.
RESULTS
Eighty-two patients were included with 62 (77%) of female sex. Mean age was 67±8 years; 64 patients (78%) were in the Ao-CTA+/PET+ group; 17 (22%) in the Ao-CTA-/PET+ group and 1 had aortitis only on CTA. Overall, 51 (62%) patients had at least one relapse during follow-up: 45/64 (70%) in the Ao-CTA+/PET+ group and 5/17 (29%) in the Ao-CTA-/PET+ group (log rank, p = 0.019). In multivariate analysis, aortitis on CTA (Hazard Ratio 2.90, p = 0.03) was associated with an increased risk of relapse.
CONCLUSION
Positivity of both CTA and FDG-PET/CT for GCA-related aortitis was associated with an increased risk of relapse. Aortic wall thickening on CTA was a risk factor of relapse compared with isolated aortic wall FDG uptake.

Identifiants

pubmed: 36801668
pii: S0049-0172(23)00012-4
doi: 10.1016/j.semarthrit.2023.152172
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
Radiopharmaceuticals 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152172

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Authors have no conflict of interest for this study.

Auteurs

Victor Genin (V)

Nantes Université, CHU Nantes, Department of internal and vascular medicine, F-44000 Nantes, France.

Jean-François Alexandra (JF)

Department of Internal Medicine, Bichat Hospital, Paris, France.

Hubert de Boysson (H)

Department of Internal Medicine, Caen University Hospital, Caen, France.

Laurent Sailler (L)

Department of Internal Medicine, University Hospital of Toulouse, Toulouse, France.

Maxime Samson (M)

Department of Internal Medicine and Clinical Immunology, University Hospital, Dijon, France.

Brigitte Granel (B)

Department of Internal Medicine, University Hospital of Marseille, Marseille, France.

Karim Sacre (K)

Department of Internal Medicine, Bichat Hospital, Paris, France.

Thomas Quéméneur (T)

Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France.

Clémentine Rousselin (C)

Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France.

Geoffrey Urbanski (G)

Department of Internal Medicine and Clinical Immunology, Angers University Hospital, Angers, France.

Julie Magnant (J)

Department of Internal Medicine, CHRU Tours, Tours, France.

Valérie Devauchelle-Pensec (V)

Department of Rheumatology, University Hospital La Cavale Blanche, Brest, France.

Viviane Queyrel-Moranne (V)

Department of Internal Medicine, CHU Nice, Nice, France.

Mickaël Martin (M)

Department of Internal Medicine and Infectious Diseases, CHU Poitiers, Poitiers, France.

Emmanuel Héron (E)

Department of Internal Medicine, Hospital Quinze-Vingts, Internal Medicine, Paris, France.

Aurélie Daumas (A)

Department of Internal Medicine, University Hospital of Marseille, Marseille, France.

Quentin Gomes de Pinho (QG)

Department of Internal Medicine, University Hospital of Marseille, Marseille, France.

Bastien Jamet (B)

Nantes Université, CHU Nantes, Department of nuclear medicine, F-44000 Nantes, France.

Jean-Michel Serfaty (JM)

Nantes Université, CHU Nantes, Department of cardiovascular imaging, F-44000 Nantes, France.

Christian Agard (C)

Nantes Université, CHU Nantes, Department of internal and vascular medicine, F-44000 Nantes, France.

Olivier Espitia (O)

Nantes Université, CHU Nantes, Department of internal and vascular medicine, F-44000 Nantes, France. Electronic address: olivier.espitia@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH